Raloxifene-d4 (hydrochloride)

Raloxifene-d₄ is intended for use as an internal standard for the quantification of raloxifene by GC- or LC-MS. Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits estrogenic activity in bone cells without stimulating breast or uterine tissues.¹ Raloxifene guards endothelial cells obtained from rat aortic rings against oxidative insult (1 µM) and lowers serum cholesterol in ovariectomized rodents (ED₅₀ = 0.2 mg/kg).^2,1 Formulations containing raloxifene have been shown to reduce bone resorption and promote bone formation in post-menopausal women.³

1.Black, L.J., Sato, M., Rowley, E.R., et al.Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized ratsJ. Clin. Invest.93(1)63-69(1994) 2.Wong, C.M., Yung, L.M., Leung, F.P., et al.Raloxifene protects endothelial cell function against oxidative stressBr. J. Pharmac.155(3)326-334(2008) 3.Özmen, B., Kirmaz, C., Aydin, K., et al.Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-α, TGF-ß1 and bone turnover markers in the treatment of postmenopausal osteoporosisEur. Cyto. Netw.18(3)148-153(2007)